

patients with AF across different specialties and may inform development of tailored education interventions.

## Supplementary material

Supplementary material is available at *Europace* online.

## Acknowledgements

The production of this document is under the responsibility of the Scientific Initiatives Committee of the European Heart Rhythm Association: Tatjana S. Potpara (Chair), Radoslaw Lenarczyk (Co-Chair), Giulio Conte, Gheorghe Andrei Dan, Michal M. Farkowski, Malcolm Finlay, Estelle Gandjbakhch, Konstantinos E. Iliodromitis, Kristine Jubele, Deirdre A. Lane, Eloi Marijon, Francisco Marin, Frits Prinzen, and Daniel Scherr. This work was also planned as part of the activity of the European Renal and Cardiovascular Medicine (EURECAm) working group of the European Renal Association–European Dialysis and Transplantation Association (ERA-EDTA).

**Conflict of interest:** none declared.

## References

- Potpara TS, Ferro CJ, Lip G. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. *Nat Rev Nephrol* 2018;**14**:337–51.
- Boriani G, Savelieva I, Dan GA, Deharo JC, Ferro C, Israel CW *et al*. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making—a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. *Europace* 2015;**17**:1169–96.
- Lip GYH, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: past, present and future. *Thromb Haemost* 2017;**117**:1230–9.
- Potpara TS, Jokic V, Dagnes N, Larsen TB, Lane DA, Hindricks G *et al*. Non-vitamin K oral anticoagulant drugs for stroke prevention in patients with atrial fibrillation and chronic kidney disease. *Curr Med Chem* 2016;**23**:2055–69.
- Heidbuchel H, Dagnes N, Antz M, Kuck KH, Lazure P, Murray S *et al*. Major knowledge gaps and system barriers to guideline implementation among European physicians treating patients with atrial fibrillation: a European Society of Cardiology international educational needs assessment. *Europace* 2018;**20**:1919–28.
- Ptaszek LM, Baugh CW, Lubitz SA, Ruskin JN, Ha G, Forsch M *et al*. Impact of a multidisciplinary treatment pathway for atrial fibrillation in the emergency department on hospital admissions and length of stay: results of a multi-center study. *J Am Heart Assoc* 2019;**8**:e012656.
- Gallagher C, Elliott AD, Wong CX, Rangnekar G, Middeldorp ME, Mahajan R *et al*. Integrated care in atrial fibrillation: a systematic review and meta-analysis. *Heart* 2017;**103**:1947–53.
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B *et al*. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Europace* 2016;**18**:1609–78.
- Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M *et al*. EORP-AF Long-Term General Registry Investigators. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. *Europace* 2018;**20**:747–57.
- Potpara TS, Dan GA, Trendafilova E, Goda A, Kusljagic Z, Manola S *et al*. BALKAN-AF Investigators. Stroke prevention in atrial fibrillation and 'real world' adherence to guidelines in the Balkan Region: the BALKAN-AF Survey. *Sci Rep* 2016;**6**:20432.
- Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B *et al*. Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report. *Chest* 2018;**154**:1121–201.
- Potpara TS, Lenarczyk R, Larsen TB, Deharo JC, Chen J, Dagnes N. Management of atrial fibrillation in patients with chronic kidney disease in Europe Results of the European Heart Rhythm Association Survey. *Europace* 2015;**17**:1862–7.
- Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD *et al*. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014;**383**:955–62.
- Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L *et al*. ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. *Europace* 2018;**20**:1231–42.
- Harel Z, Chertow GM, Shah PS, Harel S, Dorian P, Yan AT *et al*. Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and meta-analysis. *Can J Cardiol* 2017;**33**:737–46.
- Siontis KC, Zhang X, Eckard A, Bhavne N, Schaubel DE, He K *et al*. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. *Circulation* 2018;**138**:1519–29.
- Coleman CI, Kreutz R, Sood NA, Bunz TJ, Eriksson D, Meinecke AK *et al*. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis. *Am J Med* 2019;**132**:1078–83.
- Fernandez-Prado R, Castillo-Rodriguez E, Velez-Arribas FJ, Gracia-Iguacel C, Ortiz A. Creatinine clearance is not equal to glomerular filtration rate and Cockcroft-Gault equation is not equal to CKD-EPI collaboration equation. *Am J Med* 2016;**129**:1259–63.

## Corrigendum

doi:10.1093/europace/euz365

**Corrigendum to:** 2019 HRS/EHRA/APHRs/LAHRs expert consensus statement on catheter ablation of ventricular arrhythmias [*Europace* 2019;**21**:1143–4]

In this expert consensus statement, Figure 5 has been modified for clarity to illustrate the inner loop and to include a supporting reference in the figure legend. Please refer to the text of subsection 8.3.1 “Entrainment Mapping: Overview” and the references for further discussion. The figure is shown correctly below and has been corrected online.

© 2020 The Heart Rhythm Society, the European Heart Rhythm Association, a registered branch of the European Society of Cardiology, the Asia Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society. Published by Elsevier Inc./Oxford University Press/Wiley. This article is published under the Creative Commons CC-BY license.